Incorporating Precision Medicine Into the Treatment of NSCLC

Article

Dr. Kim discusses why non-small cell lung cancer should be considered the paradigm for precision medicine, and how treatment of the disease has changed over the last decade.

Edward Kim, MD, FACP, of the Levine Cancer Institute, Carolinas Healthcare System in Charlotte, North Carolina, offers insight into the changing treatment paradigms in non-small lung cancer, and why many patients can now have indivdualized therapy plans based on the genetic make-up of their disease and the advances in the field.

We spoke with Dr. Kim at the 2017 ASCO annual meeting, where he presented at an education session entitled, "Incorporating Precision Medicine Into Your Practice: How, Why, and When?"

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.